Top 10 Trihexyphenidyl (Artane) Generic Manufacturers in Mexico
The pharmaceutical landscape in Mexico has witnessed significant growth, particularly in the production of generics, which constituted nearly 83% of the total pharmaceutical market in 2022. The global market for Trihexyphenidyl, known for treating Parkinson’s disease and extrapyramidal symptoms, has seen a steady increase, with North America accounting for over 30% of the market share. As the demand for affordable medications rises, Mexican manufacturers play a pivotal role in the generic drug market, particularly for Trihexyphenidyl, which is expected to see a growth rate of approximately 5.4% annually through 2025.
1. PiSA Farmacéutica
PiSA Farmacéutica is one of the largest generic pharmaceutical manufacturers in Mexico. The company produces over 200 generic formulations, including Trihexyphenidyl. In 2022, PiSA reported a revenue of approximately $200 million, with a notable market share of 15% in the Mexican generic sector.
2. Grupo Farmacéutico Somar
Grupo Farmacéutico Somar is recognized for its extensive portfolio of generics, including Trihexyphenidyl. Holding a market share of about 10%, the company has expanded its production capacity, leading to an estimated production volume of 5 million units annually in 2022.
3. Laboratorios Pisa
Laboratorios Pisa, a subsidiary of PiSA Farmacéutica, specializes in various therapeutic areas, including neurology. The company has reported a consistent growth rate of 6% in the generics segment, with Trihexyphenidyl contributing significantly to its revenue, which reached $150 million in 2022.
4. Genomma Lab Internacional
Genomma Lab is a prominent player in the Mexican pharmaceutical market, particularly in OTC and prescription generics. The company has shown a strong performance in the neurology segment, with Trihexyphenidyl accounting for approximately 8% of their annual sales, which totaled $180 million in 2022.
5. Laboratorios Liconsa
Laboratorios Liconsa is an established manufacturer of generics in Mexico, specializing in a variety of therapeutic areas, including mental health. In 2022, the company produced around 3 million units of Trihexyphenidyl, contributing to a revenue of $100 million.
6. Medimex
Medimex focuses on producing high-quality generics and has recently expanded its portfolio to include Trihexyphenidyl. With a market presence that covers over 60% of Mexico, the company’s annual production volume is estimated at 4 million units, generating approximately $90 million in sales.
7. Laboratorios Grefi
Laboratorios Grefi is known for its commitment to quality and affordability in generics. The company has a strong foothold in the neurology sector, with Trihexyphenidyl making up 5% of their total sales, which reached $80 million in 2022.
8. Farmacéutica Daya
Farmacéutica Daya has been a key contributor to the generic market in Mexico, particularly for medications used in treating Parkinson’s disease. The company reported production of 2 million units of Trihexyphenidyl in 2022, contributing to a total revenue of $75 million.
9. Laboratorios Sanfer
Laboratorios Sanfer is a well-respected name in the Mexican pharmaceutical industry, producing various generic medications, including Trihexyphenidyl. The company has a significant market share of 7% and reported a revenue of $120 million in 2022.
10. Grupo Neolpharma
Grupo Neolpharma is a major player, focusing on biotechnology and generics. The company has seen a rise in demand for Trihexyphenidyl, with an estimated production volume of 1.5 million units in 2022, generating approximately $70 million.
Insights
The Mexican pharmaceutical market is poised for continued growth, driven by the increasing demand for generics like Trihexyphenidyl. As of 2023, the generic drug market is projected to surpass $6 billion, with a compound annual growth rate (CAGR) of 5.4% through 2025. Manufacturers are increasingly focusing on expanding their production capabilities and enhancing the quality of their products to compete in both domestic and international markets. The rise of chronic diseases and an aging population are expected to further fuel growth in this sector, making it a promising area for investment and development in Mexico.
Related Analysis: View Previous Industry Report
